Solid Biosciences Inc. (SLDB)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Shares of biotech company Solid Biosciences NASDAQ: SLDB skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%.
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
On Tuesday, Solid Biosciences Inc. SLDB released initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy.
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Initiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to $7.56 billion in 2034. Data from the first 3 patients of the phase 1/2 INSPIRE DUCHENNE study, using SGT-003 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q1 of 2025.
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia.
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Wedbush initiated coverage on Solid Biosciences, Inc. SLDB, a gene therapy company focused on treating Duchenne muscular dystrophy (DMD).
